{"id":2295,"date":"2017-12-04T20:06:18","date_gmt":"2017-12-04T20:06:18","guid":{"rendered":"https:\/\/www.medicalmarijuanainc.com\/?p=33217"},"modified":"2017-12-04T20:06:18","modified_gmt":"2017-12-04T20:06:18","slug":"mmj-reporter-trumpets-dutch-scientists-landmark-trial-tests-canchew-plus-axim-biotechnologies","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2017\/12\/04\/mmj-reporter-trumpets-dutch-scientists-landmark-trial-tests-canchew-plus-axim-biotechnologies\/","title":{"rendered":"MMJ Reporter Trumpets Dutch Scientists\u2019 Landmark Trial Tests of CanChew\u00ae Plus from AXIM\u00ae Biotechnologies"},"content":{"rendered":"

A marijuana-focused news outlet recently spotlighted MJNA investment company AXIM\u00ae<\/sup> Biotechnologies and its upcoming trial of its cannabinoid-based gum for IBS.<\/span><\/i><\/p>\n

Medical Marijuana, Inc. investment company<\/span> AXIM\u00ae<\/sup> Biotechnologies<\/span><\/a> and its cannabinoid-based gum were recently championed by <\/span>MMJ Reporter<\/span><\/i>. The leading marijuana-focused media outlet spotlighted AXIM\u00ae<\/sup> Biotechnologies\u2019 trial of its CanChew Plus\u00ae<\/sup> CBD gum for the treatment of irritable bowel syndrome (IBS).<\/span><\/p>\n

Describing the upcoming trial as \u201ca landmark for\u2026 the medical cannabis industry,\u201d the <\/span>MMJ Reporter<\/span><\/i> piece celebrated the efforts of AXIM\u00ae<\/sup> Biotechnologies what they could mean for those diagnosed with IBS, a condition with currently no valid treatment options.<\/span><\/p>\n

What is IBS?<\/b><\/h2>\n

IBS, a chronic intestinal disorder that requires long term care, affects between<\/span> 25 and 45 million people in the United States alone<\/span><\/a>, and 15 percent of the worldwide population. The syndrome, also sometimes referred to as spastic colon, causes symptoms such as:<\/span><\/p>\n